Feature | July 15, 2014

Minimally Invasive Aortic Stent Graft Repairs Prove Safer Than Surgery


July 15 2014 — Researchers at the University of California, San Diego School of Medicine have documented the safety benefits of aortic stent grafts inserted during minimally invasive surgery to repair abdominal aortic aneurysms in a study published July 9 in JAMA Surgery.

The study shows that patients who received the minimally invasive aortic repair procedure had a 42 percent reduction in preventable post-operative complications and a 72 percent reduction in mortality, compared with those who had undergone open repair surgery.

The safety of the endovascular "inside blood vessel" procedure also appears to be improving over time, as researchers documented a 37 percent reduction in the likelihood of an avoidable complication between 2003 and 2010.

The statistics are based on an analysis of 70,946 cases of abdominal aortic aneurysm repair performed over the seven-year period, culled from a nationwide hospital database maintained by the Healthcare Cost and Utilization Project.

"All this is good news for patients because endovascular repair has become the most common treatment for abdominal aortic aneurysms," said senior author John Lane, M.D., director of endovascular surgery at UC San Diego Health System and associate professor at the UC San Diego School of Medicine. The lead author is John Rose, M.D., a resident physician at UC San Diego School of Medicine.

Endovascular aortic aneurysm repair involves accessing the damaged aorta by first puncturing a blood vessel in the groin, often without making an incision, and then inserting a metallic stent that is guided using X-ray to the target area where it is then expanded. By contrast, in open repair surgery, surgeons make a large incision in the abdomen and manually sew a reinforcement graft into place.

"We have known that minimally invasive procedures are safer for patients," said Lane, who is also chief of endovascular surgery at Veterans Affairs San Diego Healthcare System. "It has been shown in randomized clinical trials and noted anecdotally. This is, however, the first time that we have been able to show that endovascular aneurysm repair is safer in terms of preventing complications in the hospital, as measured by patient safety indicators."

The value of the study, he said, is that it rigorously documents the benefits within the context of more than a dozen formally tracked patient safety indicators (PSIs), included in nationwide hospital care databases to help monitor and prevent avoidable complications during hospitalizations.

These PSIs include wound infection, blood infection (sepsis), hip fracture, accidental puncture or laceration and transfusion reaction and mortality among patients diagnosed as low-risk.

The findings represent a repeatable, statically defensible method for evaluating the comparative safeties of different surgical treatment options, particularly new methods.

"Medical errors and patient safety are an ongoing concern with any new surgical innovation," said David C. Chang, Ph.D., MPH, MBA, director of outcomes research at UC San Diego School of Medicine and a co-author. "This study shows the value in monitoring the safety of innovations. Patients need to keep this type of information in mind when considering different treatment options."

For more information: www.health.ucsd.edu


Related Content

News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
Subscribe Now